Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort

International Journal of Cancer

Volumn 127, Issue 4, 2010, Pages 961-967

  Nimeus Malmstrom E ^a   Koliadi, A ^b   Ahlin, C ^b   Holmqvist, M ^c   Holmberg, L ^c,d   Amini, R M ^b   Jirstrom K ^a   Warnberg F ^b   Blomqvist, C ^b   Ferno M ^a   Fjallskog M L ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Regional Cancer Centre Uppsala Orebro   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Cyclin B1; Proliferation marker; Reproducibility

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; TUMOR MARKER; CCNB1 PROTEIN, HUMAN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; LUNG CARCINOMA; LYMPH NODE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SURVIVAL RATE; SWEDEN; TISSUE MICROARRAY;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLIN B1; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPH NODES; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; SWEDEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954737040     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25091     Document Type: Article

References (29)

1. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(3):R25. (Pubitemid 43827376)
2. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364(9437):858-68.
3. Early Breast Cancer Trialists' Collaborative Group; Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-1717.
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009;20(8): 1319-29. Epub 2009 Jun 17
5. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93(2):283-87. (Pubitemid 32574286)
6. Michalides R, van Tinteren H, Balkenende A, et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002;86(3):402-8. (Pubitemid 34185125)
7. Kuhling H, Alm P, Olsson H, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003;199(4):424-31. (Pubitemid 36411218)
8. Rudolph P, Kuhling H, Alm P, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer. 2003;105(5):674-80. (Pubitemid 36687736)
9. de Azambuja E, Cardoso F, de Castro G, Jr., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96(10):1504-13. (Pubitemid 46762956)
10. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol. 2005;23(25):5993-6001. (Pubitemid 46300216)
11. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Breast Cancer Res Treat 1993;28(1):55-9.
12. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18(7):1133-44.
13. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312.
14. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10(4):R65.
15. Smits VA, Medema RH. Checking out the G(2)/M transition. Biochim Biophys Acta 2001;1519(1-2):1-12.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. (Pubitemid 40051905)
17. Suzuki T, Urano T, Miki Y, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007;98(5):644-51. (Pubitemid 46563439)
18. Aaltonen K, Amini RM, Heikkila P, et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009;100(7):1055-60.
19. Eaker S, Dickman PW, Hellstrom V, Zack MM, Ahlgren J, Holmberg L. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev 2005;14(12):2914-18. (Pubitemid 43068824)
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-10.
21. Altman D. Practical Statistics for Medical Research. London, UK: Chapman & Hall; 1991.
22. Koliadi AN, C. Ahlin, C. Fjällskog, M-L. Cyclin B as a prognostic factor in low-risk node negative breast cancer. Cancer Res 2009;69(Suppl.)(2).
23. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007;51(4):491-8.
24. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52(1-3):227-37.
25. Poikonen P, Sjostrom J, Amini RM, Villman K, Ahlgren J, Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005;93(5):515-19. (Pubitemid 43079993)
26. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159(6):2249-56. (Pubitemid 33104278)
27. Gillett CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000;192(4):549-53.
28. Boiesen P, Bendahl PO, Anagnostaki L, et al. Histologic grading in breast cancer - reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000;39(1):41-5. (Pubitemid 30216614)
29. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98(4):262-72. (Pubitemid 43264710)